Understanding multiple myeloma genetics and treatment outcomes
Integrative Oncogenomics of Multiple Myeloma
['FUNDING_P01'] · DANA-FARBER CANCER INST · NIH-11387058
This program looks at how genetic and molecular features of multiple myeloma relate to patient outcomes and whether high‑dose therapy helps people who become minimal residual disease (MRD) negative.
Quick facts
| Phase | ['FUNDING_P01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | DANA-FARBER CANCER INST (nih funded) |
| Locations | 1 site (BOSTON, UNITED STATES) |
| Trial ID | NIH-11387058 on ClinicalTrials.gov |
What this research studies
At Dana‑Farber and partner centers, researchers combine lab work and clinical trials to learn how genes and cell changes in multiple myeloma affect treatment results. They are using samples and data from a large randomized group of about 716 patients to see whether people who become MRD‑negative still benefit from high‑dose therapy and transplant. The team will perform detailed DNA and RNA sequencing, study epigenetic changes, and build risk models linking these molecular patterns to outcomes. Results and data tools will be shared through a public portal so doctors and patients can use the findings.
Who could benefit from this research
Good fit: Adults with multiple myeloma who are receiving initial therapy, are eligible for high‑dose therapy/autologous stem cell transplant, or are willing to donate blood or bone marrow samples for research.
Not a fit: People without multiple myeloma, those not eligible for transplant, or those unwilling to provide samples are unlikely to be eligible or directly benefit from this program.
Why it matters
Potential benefit: If successful, this work could help doctors personalize care by identifying patients who can safely avoid intensive high‑dose transplant and those who need more aggressive treatment.
How similar studies have performed: Earlier studies have shown MRD is a powerful predictor and some transplant trials exist, but combining a large randomized trial with deep genomic and epigenomic profiling is a newer approach.
Where this research is happening
BOSTON, UNITED STATES
- DANA-FARBER CANCER INST — BOSTON, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: MUNSHI, NIKHIL C. — DANA-FARBER CANCER INST
- Study coordinator: MUNSHI, NIKHIL C.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.